CTLA4 and neoplasm: This mechanistic insight directly explained why TGF‐β blockade achieved superior anti‐tumour efficacy compared with PD‐1/CTLA‐4 inhibition in our in vivo model, highlighting the translational potential of targeting this pathway in GCB‐DLBCL.